Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines

作     者：Cecilia Vasti Cecilia M Hertig 

作者机构：Laboratory of Molecular CardiologyInstitute for Research in Genetic Engineering and Molecular Biology - Dr. Hector N. Torres- (INGEBI)1428 Buenos AiresArgentina 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2014年第6卷第7期

页      面：653-662页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by National Research Council of Argentina CONICET PIP N°0722 

主　　题：Ventricular dilation Cardiotoxicity Erbb2 Erbb4 Neuregulin Trastuzumab Doxorubicin 

摘      要：Neuregulin-1(NRG1)signaling through the tyrosine kinase receptors erbB2 and erbB4 is required for cardiac morphogenesis,and it plays an essential role in maintaining the myocardial architecture during *** tyrosine kinase receptor erbB2 was first linked to the amplification and overexpression of erbb2 gene in a subtype of breast tumor cells,which is indicative of highly proliferative cells and likely a poor prognosis following conventional *** development of targeted therapies to block the survival of erbB2-positive cancer cells revealed that impaired NRG1 signaling through erbB2/erbB4 heterodimers combined with anthracycline chemotherapy may lead to dilated cardiomyopathy in a subpopulation of treated *** ventricular-specific deletion of either erbb2 or erbb4 manifested dilated cardiomyopathy,which is aggravated by the administration of *** on the exacerbated toxicity displayed by the combined treatment,it is expected that the relevant pathways would be affected in a synergistic *** review examines the NRG1 activities that were monitored in different model systems,focusing on the emerging pathways and molecular targets,which may aid in understanding the acquired dilated cardiomyopathy that occurs under the conditions of NRG1-deficient signaling.